Search results
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer - Barinthus...
Benzinga· 20 hours agoBarinthus Biotherapeutics plc BRNS, formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates ...
CDC says it’s identified 1st documented cases of HIV transmitted through cosmetic needles
WJTV Jackson· 3 days agoALBUQUERQUE, N.M. (AP) — Three women who were diagnosed with HIV after getting “vampire facial”...
What's Going On With CytomX Stock? - CytomX Therapeutics (NASDAQ:CTMX)
Benzinga· 15 hours agoCytomX Therapeutics, Inc. CTMX shares are racing higher Wednesday. CytomX and Amgen, Inc. AMGN are...
Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with...
Casper Star-Tribune· 6 days agoArbele, a clinical-stage biotechnology company focused on the development of novel immunotherapies targeted for advanced gastrointestinal cancers, today announced the positive recommendation ...
A New Weapon Against Cancer: Checkpoint Inhibitors, A Double-Edged Sword
Forbes· 3 days agoThis article joins a growing series on mono cancer treatments, including novel immunotherapies such...
Getting Under the Skin at May 11 Symposium on Melanoma
Newswise· 2 hours agoLOS ANGELES (May 2, 2024) -- The Angeles Clinic and Research Institute, an affiliate of Cedars-Sinai Cancer, is teaming up with the AIM at Melanoma Foundation for the 14th year to host a free ...
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to...
Morningstar· 3 days agoRepertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced ...
Keto supplement may improve immunotherapy for prostate cancer
Futurity· 2 days agoAdding a pre-ketone supplement, a component of a high-fat, low-carb ketogenic diet, to a type of...
Scientists develop new organoid model to study thymus function
Medical Xpress· 3 days agoIt is the first laboratory model that enables long-term culture of TECs, which presents new opportunities to study their function. Ultimately, this could also bring new insights into the treatment ...
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to...
CBS 47 Fresno· 3 days agoRepertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced ...
